People · Operator
Named in public records as an officer, director or promoter · active 2014–2023 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| X4 Pharmaceuticals, Inc | — | Biotechnology | Series C | $320.3M | $495.3M | 2023 |
| Tvardi Therapeutics, Inc. | — | Pharmaceuticals | Series C | $78.1M | $1.8B | 2021 |
| X4 Pharmaceuticals, Inc. | — | Pharmaceuticals | Series B | $73.2M | $1.2B | 2017 |
| Mereo Biopharma Group plc | — | Pharmaceuticals | Series C | $70.0M | $2.5B | 2020 |
| Prosensa Holding N.V. | — | Biotechnology | Series C | $50.5M | $2.1B | 2014 |
Michael Wyzga at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Michael Wyzga on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Adam Mostafa | 2 | 3 |
| Alison Lawton | 2 | 3 |
| Paula Ragan | 2 | 3 |
| Carl Gordon | 1 | 24 |
| Michael Ross | 1 | 18 |
| Isaac Blech | 1 | 14 |
| Amy Schulman | 1 | 11 |
| Terrance McGuire | 1 | 9 |
| David Mott | 1 | 9 |
| Annalisa Jenkins | 1 | 8 |
| CARL L. GORDON | 1 | 7 |
| Michael Gray | 1 | 6 |
| Michael Gilman | 1 | 6 |
| Tillman U. Gerngross | 1 | 5 |
| Claudio Nessi | 1 | 5 |
| Tillman Gerngross | 1 | 5 |
| Errik B. Anderson | 1 | 5 |
| Robert L. Birnbaum | 1 | 4 |
| Daniel Burgess | 1 | 4 |
| Luc Dochez | 1 | 4 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.